These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 15489838)

  • 21. Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus.
    Playford DA; Watts GF; Best JD; Burke V
    Am J Cardiol; 2002 Dec; 90(11):1254-7. PubMed ID: 12450611
    [No Abstract]   [Full Text] [Related]  

  • 22. Combination lipid therapy in type 2 diabetes.
    Sacks FM; Carey VJ; Fruchart JC
    N Engl J Med; 2010 Aug; 363(7):692-4; author reply 694-5. PubMed ID: 20842772
    [No Abstract]   [Full Text] [Related]  

  • 23. Apolipoprotein A-V genetic variation and plasma lipoprotein response to fibrates.
    Hegele RA; Pollex RL
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1224-7. PubMed ID: 17522394
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy.
    Corbelli JC; Bullano MF; Willey VJ; Cziraky MJ; Corbelli ME; Waugh W
    Am J Cardiol; 2002 Dec; 90(12):1388-91. PubMed ID: 12480052
    [No Abstract]   [Full Text] [Related]  

  • 26. Updating a 12-year experience with arrest and reversal therapy for coronary heart disease (an overdue requiem for palliative cardiology).
    Esselstyn CB
    Am J Cardiol; 1999 Aug; 84(3):339-41, A8. PubMed ID: 10496449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.
    Vakkilainen J; Steiner G; Ansquer JC; Perttunen-Nio H; Taskinen MR
    Diabetes Care; 2002 Mar; 25(3):627-8. PubMed ID: 11874962
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term fenofibrate therapy increases fibroblast growth factor 21 and retinol-binding protein 4 in subjects with type 2 diabetes.
    Ong KL; Rye KA; O'Connell R; Jenkins AJ; Brown C; Xu A; Sullivan DR; Barter PJ; Keech AC;
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4701-8. PubMed ID: 23144467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?
    Colhoun H
    Lancet; 2005 Nov; 366(9500):1829-31. PubMed ID: 16310536
    [No Abstract]   [Full Text] [Related]  

  • 30. [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
    Pérez A
    Endocrinol Nutr; 2010 Dec; 57(10):457-9. PubMed ID: 20688585
    [No Abstract]   [Full Text] [Related]  

  • 31. Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.
    Stulc T; Melenovský V; Grauová B; Kozich V; Ceska R
    Nutrition; 2001 Sep; 17(9):721-3. PubMed ID: 11527658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correction to the FIELD study report.
    Keech A; Simes J; Barter P; Best J; Scott R; Taskinen MR;
    Lancet; 2006 Oct; 368(9545):1415. PubMed ID: 17055933
    [No Abstract]   [Full Text] [Related]  

  • 33. [Antilipemic therapy in dyslipidemias in obese non-insulin-dependent diabetics (ONIDDM)].
    Palel G; Coman A; Petrovanu R; Ungureanu D; Cojocaru M
    Rev Med Chir Soc Med Nat Iasi; 1997; 101(3-4):120-2. PubMed ID: 10756782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
    Farnier M; Steinmetz A; Retterstøl K; Császár A
    Clin Ther; 2011 Jan; 33(1):1-12. PubMed ID: 21397769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fenofibrate in the treatment of dyslipidemia associated with HIV infection.
    Samineni D; Fichtenbaum CJ
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):995-1004. PubMed ID: 20604734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of fenofibrate and gemfibrozil on plasma homocysteine.
    Bostom AG
    Lancet; 2001 Nov; 358(9295):1811-2. PubMed ID: 11734262
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of fibrates on serum metabolic parameters.
    Elisaf M
    Curr Med Res Opin; 2002; 18(5):269-76. PubMed ID: 12240789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on fenofibrate.
    Guay DR
    Cardiovasc Drug Rev; 2002; 20(4):281-302. PubMed ID: 12481201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.